Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Pretax Margin % Related Terms
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Pretax Margin % Chart
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Pretax Margin % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) has a Pretax Margin % of 12.82% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents and its competitors. This is 28% below median its historical median of 17.89. Over the past decade, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' Pretax Margin % has ranged from 10.35 to 22.13. According to the industry distribution chart, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents ranks #391 out of 957 companies in the Drug Manufacturers industry, placing it in the top 40.9%.
Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' Pretax Margin % too high?
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' current Pretax Margin % of 12.82% is 28% below median its 10-year median of 17.89. Over the past 10 years, this metric has ranged from a low of 10.35 to a high of 22.13. The Drug Manufacturers industry median Pretax Margin % is 7.43. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' value of 12.82% is 72.5% above this industry median. Based on the distribution chart, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents ranks #391 out of 957 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents has a GF Score™ of 83/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents ranks #391 out of 957 companies for Pretax Margin %. This puts Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents in the upper half of its industry. The industry median Pretax Margin % is 7.43. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' value of 12.82% is 72.5% above this benchmark. Historically, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' own Pretax Margin % has ranged from 10.35 to 22.13 over the past decade. While the company's 10-year median is 17.89 vs. the industry median of 7.43, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.43, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's current Pretax Margin % of 12.82% is 72.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's current Pretax Margin % is 12.82%, which is 28% below median its own 10-year median of 17.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents stock overvalued right now?
Based on GuruFocus' analysis, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) is currently considered Significantly Overvalued. The stock's GF Value™ is E£4.17, compared to a current price of E£6.20 — trading 48.7% above its estimated fair value. The current Pretax Margin % is 12.82%, which is 28% below median its 10-year median of 17.89 and 72.5% above the Drug Manufacturers industry median of 7.43. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' overall GF Score™ is 83/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA), the current Pretax Margin % is 12.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) Overvalued in 2026?
Based on GuruFocus' analysis, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents stock appears to be overvalued.
The current stock price of E£6.20 is trading 48.7% above its estimated GF Value™ of E£4.17.
GuruFocus considers Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents to be Significantly Overvalued.
Key valuation signals for CAI:RMDA:
Pretax Margin %: 12.82% (28% below median its 10-year median of 17.89)
GF Value™: E£4.17 vs. price of E£6.20 (48.7% above fair value)
Industry Position: 72.5% above the Drug Manufacturers median (#391 of 957)
No single metric tells the full story. See the CAI:RMDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents is a pharmaceutical company. The company is engaged in the Manufacturing, marketing, selling and storing of pharmaceutical reagents for human and veterinary use; manufacturing, marketing, selling and storing of diagnostic reagents necessary for individuals, laboratories and hospitals; importing pharmaceutical reagents and raw materials necessary for serving the its purposes without trading; producing pharmaceutical reagents for human and veterinary and diagnostic use for others and by others; and producing food supplements for human use for others and by others. It has two segments: production and selling of pharmaceutical products, which generates maximum revenue; and manufacturing for others (Toll manufacturing).
83GF Score
Get the complete analysis for CAI:RMDA
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:RMDA has been successfully added to your 
